Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
302.78 -7.74 (-2.49%) 04/08/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 302.78 unch (unch) 16:00 ET
Quote Overview for Tue, Apr 8th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
300.22
Day High
325.80
Open 323.64
Previous Close 310.52 310.52
Volume 342,900 342,900
Avg Vol 309,875 309,875
Stochastic %K 22.27% 22.27%
Weighted Alpha -2.16 -2.16
5-Day Change -21.20 (-6.54%) -21.20 (-6.54%)
52-Week Range 189.00 - 377.46 189.00 - 377.46
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,856,278
  • Shares Outstanding, K 22,080
  • Annual Sales, $ 180,130 K
  • Annual Income, $ -465,890 K
  • EBIT $ -498 M
  • EBITDA $ -495 M
  • 60-Month Beta -0.69
  • Price/Sales 38.54
  • Price/Cash Flow N/A
  • Price/Book 9.09

Options Overview Details

View History
  • Implied Volatility 82.86% ( +7.02%)
  • Historical Volatility 67.68%
  • IV Percentile 93%
  • IV Rank 78.90%
  • IV High 93.93% on 10/18/24
  • IV Low 41.48% on 08/19/24
  • Put/Call Vol Ratio 4.65
  • Today's Volume 712
  • Volume Avg (30-Day) 487
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 19,425
  • Open Int (30-Day) 20,116

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -3.66
  • Number of Estimates 8
  • High Estimate -2.71
  • Low Estimate -4.91
  • Prior Year -7.38
  • Growth Rate Est. (year over year) +50.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
290.50 +4.23%
on 04/07/25
Period Open: 331.41
350.50 -13.61%
on 03/25/25
-28.63 (-8.64%)
since 03/07/25
3-Month
266.44 +13.64%
on 01/15/25
Period Open: 333.39
377.46 -19.78%
on 02/26/25
-30.61 (-9.18%)
since 01/08/25
52-Week
189.00 +60.20%
on 04/26/24
Period Open: 248.64
377.46 -19.78%
on 02/26/25
+54.14 (+21.77%)
since 04/08/24

Most Recent Stories

More News
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

MDGL : 302.78 (-2.49%)
Why Madrigal Pharmaceuticals Stock Is Soaring Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and...

MDGL : 302.78 (-2.49%)
Madrigal: Q4 Earnings Snapshot

Madrigal: Q4 Earnings Snapshot

MDGL : 302.78 (-2.49%)
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffraâ„¢ (resmetirom) in Patients with Compensated MASH Cirrhosis

MDGL : 302.78 (-2.49%)
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffraâ„¢ (resmetirom) in Patients with Compensated MASH Cirrhosis

MDGL : 302.78 (-2.49%)
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

MDGL : 302.78 (-2.49%)
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

MDGL : 302.78 (-2.49%)
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (NASDAQ: MDGL) stock out of the doldrums over the past few trading...

MDGL : 302.78 (-2.49%)
GS : 462.22 (-0.71%)
Why Madrigal Pharmaceuticals Stock Is Sinking Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full-year 2024...

MDGL : 302.78 (-2.49%)
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

MDGL : 302.78 (-2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 344.56
2nd Resistance Point 335.18
1st Resistance Point 318.98
Last Price 302.78
1st Support Level 293.40
2nd Support Level 284.02
3rd Support Level 267.82

See More

52-Week High 377.46
Fibonacci 61.8% 305.47
Last Price 302.78
Fibonacci 50% 283.23
Fibonacci 38.2% 260.99
52-Week Low 189.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades